Balantidiasis is a rare disease caused by bacterial species Balantidium coli. It is a type of intestinal infection commonly observed in pigs.
Balantidiasis is a rare disease caused by bacterial species Balantidium coli. It is a type of intestinal infection commonly observed in pigs. However, cases of human infection have been reported owing to poor hygiene practices, consumption of undercooked pork, and increase in trend of swine farming. The disease is predominant in tropical regions such as Brazil, New Guinea, and southern Iran.
Read Report Overview - https://www.transparencymarketresearch.com/balantidiasis-diagnosis-treatment-market.html
Symptoms of the disease include mild to moderate diarrhea, abdominal discomfort, and acute inflammation of the intestine. These are quite similar to symptoms of other intestinal inflammatory conditions such as amoebic dysentery. Balantidium infection can be diagnosed with microscopy and sigmoidoscopy examination.
Rise in prevalence of balantidiasis infection, surge in the trend of swine farming, increase in research and development activities for the diagnosis of the disease, and rise in awareness about the treatment options are the major factors projected to propel the balantidiasis diagnosis and treatment market during the forecast period. A study conducted by the Stanford University revealed that incidence of the infection have been reported in Bolivia, Papua New Guinea, and the Philippines.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=57291
The prevalence rate of the balantidiasis infection is lower than 1%. Lower incidence rate in the major pharmaceutical markets such as North America and Europe and competition between already established players are likely to restrain the global balantidiasis diagnosis and treatment market in terms of revenue during the forecast period.
The global balantidiasis diagnosis and treatment market can be segmented based on diagnosis, product type, end-user, and region. In terms of diagnosis, the market can be classified into microscopy stool examination, sigmoidoscopy, biopsy, and others. Based on product type, the global balantidiasis diagnosis and treatment market can be categorized into tetracycline, iodoquinol, and metronidazole. Tetracycline is the most prescribed drug, with proven efficiency against the bacterial strains of Balantidium coli. In terms of end-user, the balantidiasis diagnosis and treatment market can be divided into hospitals, clinics, and others.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=57291
Based on region, the global balantidiasis diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The disease is less frequently observed among the population in the developed regions such as North America and Europe. However, disease prevalence is significantly higher in the underdeveloped and developing regions such as Asia Pacific, Latin America, and Middle East & Africa.
Asia Pacific is projected to dominate the global balantidiasis diagnosis and treatment market owing to presence of large population, rise in prevalence of balantidiasis infections, economic growth, and increase in health awareness among the population. Middle East & Africa is anticipated to be second largest market for balantidiasis diagnosis and treatment due to lack of hygiene and sanitation in the rural areas. North America is expected to account for the smallest market share owing to rare occurrence of the disease due to high standards of personal hygiene practices followed by the population.
Pre Book Balantidiasis Diagnosis and Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=57291<ype=S
Key players operating in the global balantidiasis diagnosis and treatment market include Pfizer, Inc., Abbott, GlaxoSmithKline plc, Novopharm Limited, Physicians Total Care, Inc., Sandoz International GmbH, Amneal Pharmaceuticals LLC., Sanofi, Allergan, and Apotex, Inc.
Browse more Reports by Transparency Market Research:
Pulmonary Arterial Hypertension (PAH) Market: Various treatment are available in the market that helps in controlling and slowing down the growth of the diseases and improves the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the pulmonary arterial hypertension (PAH) market growth.
Global mHealth Apps Market: Development of the market seems positive with surging demand and investing resources in wearable tech businesses. These new companies center around mHealth classes, for example, women’s health, personal safety, and hydration monitoring, which guarantee energizing prospects for the global mhealth apps market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/